- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Iroko Pharmaceuticals, LLC and iCeutica, Inc. announce Iroko's acquisition of worldwide rights to two products formulated by iCeutica's proprietary Encapsulated Organic Nanoparticle (EON™) Platform technology. In addition, Iroko and iCeutica will collaborate on the application of iCeutica's EON Platform to reformulate an internal proprietary Iroko product. Iroko will guide progression of these EON formulated products through the regulatory process and ultimate launch.
"We are very pleased to announce this collaboration with iCeutica. The EON formulated products Iroko has acquired can have significant, relevant benefits for patients, in enhancing onset of action and reducing side effects," said Iroko President and CEO, John Vavricka.
"This transaction represents our first major transaction with a Pharmaceutical Company and further validates the value proposition of the EON Platform. Our team is very impressed with Iroko's highly credible and experienced team and looks forward to Iroko driving the first EON reformulated product to market," stated iCeutica CEO, Matt Callahan.
About Iroko Pharmaceuticals, LLC
Iroko is a pharmaceutical company focused on specialty therapeutic areas. The company acquires, develops, and maximizes the potential of currently marketed pharmaceutical products. Iroko increases the revenues of acquired products through focused selling and marketing efforts and product life cycle management activities including development of relevant formulations to improve patient treatment.
About iCeutica Inc: iCeutica commercializes products developed utilizing their proprietary EON™ Platform. EON is an enabling reformulation technology which provides low cost solutions to extend the life cycle of marketed products, as well as to become a cornerstone drug delivery technique for new chemical entities. The EON Platform provides a simple and scalable process to reformulate a range of different drugs.
For more information, please click here
Lisa Gray, Managing Partner
Phoenix IP Ventures
Copyright © Iroko Pharmaceuticals, LLCIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
GLOBALFOUNDRIES Expands Partner Program to Speed Time-to-Market of FDX™ Solutions: Increased support affirms FDXcelerator™ Program’s vital role in promoting broader deployment of GLOBALFOUNDRIES’ FDX™ portfolio December 15th, 2016
Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016